For 2022 full year guidance, the Company estimates revenues between $375 million and $385 million, Adjusted EBITDA between $201 million and $207 million and Adjusted non-GAAP earnings per diluted share of between $5.36 and $5.50, excluding share-based compensation, amortization of acquired intangibles and the impact of unanticipated items, in the case of adjusted non-GAAP net income, net of tax.
Novavax Receives Full Marketing Authorization For Prototype COVID-19 Vaccine Nuvaxovid In United Kingdom
Full authorization of prototype enables rapid authorization of updated Novavax COVID-19 vaccines in futureNovavax, Inc. (NASDAQ:NVAX), a global company advancing protein-based vaccines with its Matrix-M™
